INTRODUCTION: @entity14855 inhibitors (CIs) cause substantial long-term morbidity and mortality among orthotopic liver transplantation (OLT) @entity1 . Our aim was to evaluate the effectiveness and safety of @entity618 ( @entity2098 ) among OLT @entity1 with CI-related side effects. @entity1 : Thirty three adult @entity1 , including 29 @entity1 and 4 @entity1 of mean age 57 years, underwent OLT between 1986 and 2000 under treatment with CIs (28 @entity205 and five @entity1140 ). Mean follow-up after OLT was 59 months. Adverse effects were @entity8 in 26, @entity101 in 23, and @entity2359 in two. @entity2098 was added gradually while simultaneously reducing the dosage of CI. RESULTS: After a mean 15-months follow-up of @entity2098 treatment, CIs had been withdrawn in 28 @entity1 (85%). The mean time from the initiation of @entity2098 and CI withdrawal was 5 months. During the first year of follow-up chronic @entity8 improved in 16 of 26 @entity1 (61.6%) accompanied by a decreased serum @entity1011 and @entity1133 and an increase in @entity1011 clearance. Among 13/23 (56.5%) @entity101 @entity1 , there was a significant @entity551 or the number of antihypertensive drugs (P<.05). One @entity1 with @entity2359 improved. Twenty-two @entity1 (66%) displayed adverse events: five rejections (15%) including four acute episodes, controlled by CI re-introduction, and one chronic reaction. The most frequent adverse effects were @entity281 in 10 @entity1 (30%), @entity1395 in nine (27%), @entity294 in five (15%) and @entity882 in four (12%). Nevertheless, only six @entity1 (19%) required @entity2098 dose reduction, namely, three @entity1 with GI intolerance, two with repeated @entity281 , and one with @entity417 . CONCLUSIONS: @entity2098 monotherapy improves renal function and blood pressure levels in more than 50% of @entity1 with chronic @entity8 and @entity101 after OLT. Many of the side effects of @entity2098 were mild; it was safe accompanied by a low incidence of rejection reactions.

Effectiveness and safety of XXXX as monotherapy in liver transplantation.

@entity1 :: ('9606', 'Species') :: ['men', 'patient', 'women', 'patients', 'PATIENTS'] @entity14855 :: ('CHEBI:53439', 'Chemical') :: ['Calcineurin'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal impairment', 'renal dysfunction'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension', 'hypertensive'] @entity1133 :: ('MESH:D014508', 'Chemical') :: ['urea'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity1395 :: ('MESH:D001247', 'Disease') :: ['asthenia'] @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporine'] @entity2098 :: ('CHEBI:8764', 'Chemical') :: ['MMF'] @entity281 :: ('MESH:D007239', 'Disease') :: ['herpes simplex infection', 'VHS infections'] @entity618 :: ('MESH:C063008', 'Chemical') :: ['mycophenolate mofetil'] @entity1140 :: ('MESH:D016559', 'Chemical') :: ['tacrolimus'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine'] @entity551 :: ('MESH:D007022', 'Disease') :: ['decrease in blood pressure'] @entity2359 :: ('MESH:D020258', 'Disease') :: ['neurotoxicity']
@entity618 :: (MESH:C063008,Chemical) :: ['mycophenolate mofetil']
